Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333076 | 0.92 | LMNA (0.45) | PPARANPSR1PPARGPPARDSMN1; SMN2 | |
| SCHEMBL4341195 | 0.92 | PPARA (0.43) | PPARANPSR1PPARGPPARDSMN1; SMN2 | |
| SCHEMBL4334226 | 0.92 | NPSR1 (0.49) | MMP1PPARANPSR1PPARGPPARD | |
| SCHEMBL4332223 | 0.91 | CNR1 (0.45) | MMP1PPARANPSR1PPARGPPARD | |
| SCHEMBL4335128 | 0.90 | PPARA (0.54) | MMP1PPARAPPARGPPARD | |
| SCHEMBL4334936 | 0.88 | PPARA (0.49) | PPARANPSR1PPARGPPARDSMN1; SMN2 | |
| SCHEMBL4334163 | 0.88 | MEN1 (0.45) | MMP1PPARANPSR1PPARGPPARD | |
| SCHEMBL4329663 | 0.87 | LMNA (0.43) | NPSR1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4336960 | 0.85 | LMNA (0.44) | PPARANPSR1PPARGPPARDSMN1; SMN2 | |
| SCHEMBL4328950 | 0.85 | MAPT (0.48) | PPARANPSR1PPARGPPARDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MMP1 1890/4885PPARA 339/4885NPSR1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.